Pilot Study: Alteration of Deleted in Liver Cancer1 and Phosphorylated Focal Adhesion Kinase Y397 Cytoplasmic Expression and the Prognostic Value in Advanced Epithelial Ovarian Carcinoma

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2012 Jan 25

PMID 22272086

Citations 7

Authors

Dong-Mei Fan

Hui-Rong Shi

Affiliations

Soon will be listed here.

Abstract

Background: Deletion in liver cancer gene (DLC1) and phosphorylated focal adhesion kinase (p-FAK) have recently been reported as metastasis-related genes. However, the roles and prognostic values of their expression in epithelial ovarian carcinomas (EOCs) remain unclear.

Methods: The expression and prognostic value of DLC1 and p-FAK Y397 in EOC were evaluated by immunohistochemistry and multivariate analysis.

Results: Low expression of DLC1 and high expression of p-FAK Y397 were found in the 76 cases of EOC. The expression of DLC1 and p-FAK Y397 were negatively correlated. Multivariate analysis showed that the combination of them was an independent prognostic marker of EOC (P = 0.0319).

Conclusions: DLC1 and pFAK Y397 had an association with the clinicopathologic characteristics of EOC. Expression of neither of these genes was a prognostic factor alone, but the combination revealed a significant prognostic value in the 60 cases of advanced stage EOC.

Citing Articles

Oncogenic Role of miR-200c-3p in High-Grade Serous Ovarian Cancer Progression via Targeting the 3'-Untranslated Region of DLC1.

Ankasha S, Shafiee M, Abdul Wahab N, Ali R, Mokhtar N Int J Environ Res Public Health. 2021; 18(11).

PMID: 34071861 PMC: 8198916. DOI: 10.3390/ijerph18115741.

An epigenetic signature of adhesion molecules predicts poor prognosis of ovarian cancer patients.

Chang P, Liao Y, Wang H, Chen Y, Huang R, Wang Y Oncotarget. 2017; 8(32):53432-53449.

PMID: 28881822 PMC: 5581121. DOI: 10.18632/oncotarget.18515.

Prognostic Value of Focal Adhesion Kinase (FAK) in Human Solid Carcinomas: A Meta-Analysis.

Zeng X, Li N, Ma L, Tseng Y, Zhao N, Chen S PLoS One. 2016; 11(9):e0162666.

PMID: 27637100 PMC: 5026375. DOI: 10.1371/journal.pone.0162666.

Expression of pY397 FAK promotes the development of non-small cell lung cancer.

Wang B, Qi X, Li D, Feng M, Meng X, Fu S Oncol Lett. 2016; 11(2):979-983.

PMID: 26893679 PMC: 4733957. DOI: 10.3892/ol.2015.3992.

Ambivalent role of pFAK-Y397 in serous ovarian cancer--a study of the OVCAD consortium.

Aust S, Auer K, Bachmayr-Heyda A, Denkert C, Sehouli J, Braicu I Mol Cancer. 2014; 13:67.

PMID: 24655477 PMC: 3998046. DOI: 10.1186/1476-4598-13-67.

References

Amirghofran Z, Jalali S, Hosseini S, Vasei M, Sabayan B, Ghaderi A . Evaluation of CD44 and CD44v6 in colorectal carcinoma patients: soluble forms in relation to tumor tissue expression and metastasis. J Gastrointest Cancer. 2009; 39(1-4):73-8. DOI: 10.1007/s12029-009-9062-2. View

Villedieu M, Deslandes E, Duval M, Heron J, Gauduchon P, Poulain L . Acquisition of chemoresistance following discontinuous exposures to cisplatin is associated in ovarian carcinoma cells with progressive alteration of FAK, ERK and p38 activation in response to treatment. Gynecol Oncol. 2006; 101(3):507-19. DOI: 10.1016/j.ygyno.2005.11.017. View

Pils D, Horak P, Gleiss A, Sax C, Fabjani G, Moebus V . Five genes from chromosomal band 8p22 are significantly down-regulated in ovarian carcinoma: N33 and EFA6R have a potential impact on overall survival. Cancer. 2005; 104(11):2417-29. DOI: 10.1002/cncr.21538. View

Vergote I . Prognostic factors in stage I ovarian carcinoma. Verh K Acad Geneeskd Belg. 2001; 63(3):257-71; discussion 272-6. View

Wong C, Yam J, Ching Y, Yau T, Leung T, Jin D . Rho GTPase-activating protein deleted in liver cancer suppresses cell proliferation and invasion in hepatocellular carcinoma. Cancer Res. 2005; 65(19):8861-8. DOI: 10.1158/0008-5472.CAN-05-1318. View

Yam J, Ko F, Chan C, Jin D, Ng I . Interaction of deleted in liver cancer 1 with tensin2 in caveolae and implications in tumor suppression. Cancer Res. 2006; 66(17):8367-72. DOI: 10.1158/0008-5472.CAN-05-2850. View

Yuan B, Miller M, Keck C, Zimonjic D, Thorgeirsson S, Popescu N . Cloning, characterization, and chromosomal localization of a gene frequently deleted in human liver cancer (DLC-1) homologous to rat RhoGAP. Cancer Res. 1998; 58(10):2196-9. View

Kim T, Jong H, Song S, Dimtchev A, Jeong S, Lee J . Transcriptional silencing of the DLC-1 tumor suppressor gene by epigenetic mechanism in gastric cancer cells. Oncogene. 2003; 22(25):3943-51. DOI: 10.1038/sj.onc.1206573. View

Fan T, Zhao Q, Chen J, Chen W, Pearl M . Clinical significance of circulating tumor cells detected by an invasion assay in peripheral blood of patients with ovarian cancer. Gynecol Oncol. 2008; 112(1):185-91. PMC: 2606929. DOI: 10.1016/j.ygyno.2008.09.021. View

10.

Martin L, Schilder R . Management of recurrent ovarian carcinoma: current status and future directions. Semin Oncol. 2009; 36(2):112-25. DOI: 10.1053/j.seminoncol.2008.12.003. View

11.

Chak-Lui Wong C, Wong C, Ko F, Chan L, Ching Y, Yam J . Deleted in liver cancer 1 (DLC1) negatively regulates Rho/ROCK/MLC pathway in hepatocellular carcinoma. PLoS One. 2008; 3(7):e2779. PMC: 2464714. DOI: 10.1371/journal.pone.0002779. View

12.

Goodison S, Yuan J, Sloan D, Kim R, Li C, Popescu N . The RhoGAP protein DLC-1 functions as a metastasis suppressor in breast cancer cells. Cancer Res. 2005; 65(14):6042-53. PMC: 1360170. DOI: 10.1158/0008-5472.CAN-04-3043. View

13.

Luo Y, Liang F, Zhang Z . PRL1 promotes cell migration and invasion by increasing MMP2 and MMP9 expression through Src and ERK1/2 pathways. Biochemistry. 2009; 48(8):1838-46. PMC: 2765538. DOI: 10.1021/bi8020789. View

14.

Kim T, Lee J, Kim H, Jong H, Kim T, Jung M . DLC-1, a GTPase-activating protein for Rho, is associated with cell proliferation, morphology, and migration in human hepatocellular carcinoma. Biochem Biophys Res Commun. 2007; 355(1):72-7. DOI: 10.1016/j.bbrc.2007.01.121. View

15.

Liao Y, Si L, DeVere White R, Lo S . The phosphotyrosine-independent interaction of DLC-1 and the SH2 domain of cten regulates focal adhesion localization and growth suppression activity of DLC-1. J Cell Biol. 2006; 176(1):43-9. PMC: 2063623. DOI: 10.1083/jcb.200608015. View

16.

Durkin M, Yuan B, Zhou X, Zimonjic D, Lowy D, Thorgeirsson S . DLC-1:a Rho GTPase-activating protein and tumour suppressor. J Cell Mol Med. 2007; 11(5):1185-207. PMC: 4401278. DOI: 10.1111/j.1582-4934.2007.00098.x. View

17.

Lund B, Williamson P . Prognostic factors for overall survival in patients with advanced ovarian carcinoma. Ann Oncol. 1991; 2(4):281-7. DOI: 10.1093/oxfordjournals.annonc.a057937. View

18.

Watari H, Xiong Y, Hassan M, Sakuragi N . Cyr61, a member of ccn (connective tissue growth factor/cysteine-rich 61/nephroblastoma overexpressed) family, predicts survival of patients with endometrial cancer of endometrioid subtype. Gynecol Oncol. 2008; 112(1):229-34. DOI: 10.1016/j.ygyno.2008.09.039. View

19.

Kawai K, Kitamura S, Maehira K, Seike J, Yagisawa H . START-GAP1/DLC1 is localized in focal adhesions through interaction with the PTB domain of tensin2. Adv Enzyme Regul. 2009; 50(1):202-15. DOI: 10.1016/j.advenzreg.2009.10.013. View

20.

Zhang T, Zheng J, Liu C, Lu Y . Expression of DLC-1 in clear cell renal cell carcinoma: prognostic significance for progression and metastasis. Urol Int. 2009; 82(4):380-7. DOI: 10.1159/000218524. View